Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA -Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
| BOLD Stock | USD 1.63 0.06 3.55% |
About 62% of Boundless Bio,'s investor base is looking to short. The analysis of the overall investor sentiment regarding Boundless Bio, Common suggests that many traders are alarmed. The current market sentiment, together with Boundless Bio,'s historical and current headlines, can help investors time the market. In addition, many technical investors use Boundless Bio, Common stock news signals to limit their universe of possible portfolio assets.
Boundless |
Boundless Bio , a clinical-stage oncology company interrogating extrachromosomal DNA biology to deliver transformative therapies
Read at businesswire.com
 |
Boundless Bio, Fundamental Analysis
We analyze Boundless Bio,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Boundless Bio, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Boundless Bio, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Boundless Bio, is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Boundless Bio, Common Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Boundless Bio, stock to make a market-neutral strategy. Peer analysis of Boundless Bio, could also be used in its relative valuation, which is a method of valuing Boundless Bio, by comparing valuation metrics with similar companies.
Peers
Boundless Bio, Related Equities
| ALGT | Allegiant Travel | 1.44 | ||||
| ATSG | Air Transport | 0.09 | ||||
| ELALF | El Al | 0.00 | ||||
| STM | STMicroelectronics | 0.52 | ||||
| LASR | NLIGHT | 1.98 | ||||
| UAL | United Airlines | 2.01 | ||||
| DAL | Delta Air | 7.25 |
Complementary Tools for Boundless Stock analysis
When running Boundless Bio,'s price analysis, check to measure Boundless Bio,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boundless Bio, is operating at the current time. Most of Boundless Bio,'s value examination focuses on studying past and present price action to predict the probability of Boundless Bio,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boundless Bio,'s price. Additionally, you may evaluate how the addition of Boundless Bio, to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |